AAV Upstream Production Patents: Who Leads, Where the Gaps Are 2026
Adeno Associated Virus Upstream Production Patents
41.1% of all filings sit with five assignees. 1,826 of 4,442 records in scope concentrate around a small group, while a long tail of single- and few-filing entrants fills out the rest of the ranking. Annual filings ran from 226 in 2017 to a peak of 462 in 2023, then declined to 237 by 2024 (a 42% drop from the 407 recorded in 2021). Counts for 2025 and 2026 are shown but understated, since publication typically lags filing by around 18 months and those years are still filling in.
- 1GENZYME CORP638
- 2THE TRUSTEES OF THE UNIV OF PENNSYLVANIA526
- 3EDITAS MEDICINE INC329
- 4SANGAMO THERAPEUTICS INC188
- 5AKOUOS INC145
See the full adeno associated virus upstream production analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on this landscape
Who holds the most patents in adeno associated virus upstream production?
One assignee leads with 638 of the 4,442 records in scope, well ahead of the fifth-place holder at 145. The top five assignees combined account for 41.1% of all records, and the top ten extend that to 55.9%, after which the field spreads across a long tail of smaller filers. The ranking covers 100 assignees total, so it is not a narrow top-10 or top-50 cut, but a full picture of the field’s filing activity.
Is patent filing in AAV upstream production still growing?
Filings peaked in 2023 at 462 and the complete-year count fell 42% from 407 in 2021 to 237 in 2024. That looks like a slowdown, but publication typically lags filing by around 18 months, so the 2025 and 2026 figures in this dataset are still filling in and should not be read as a real decline yet. A fair read is that activity has passed an early peak, not that the field is shrinking.
What technology areas dominate AAV upstream production patents?
The C12N subclass, covering microorganisms and genetic engineering, appears on 84.2% of the 4,442 records, making it the dominant classification by a wide margin. A61K (medicinal preparations) follows at 60.0% and C07K (peptides and proteins) at 34.1%. Analytical and testing classes such as G01N and C12Q each cover under 6% of records, marking comparatively open ground for measurement-focused claims.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Adeno Associated Virus Upstream Production covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.